Stock Market Today, May 27: Micron Extends Rally on AI Chip Momentum, U.S. Markets Inch Higher

Markets were mixed, with the S&P 500 up 0.03% to 7,521.29, the Nasdaq up 0.07%, and the Dow rising 0.36% to a record 50,644.28 on blue-chip rotation. AppLovin jumped 10% after a bullish Morgan Stanley note, Snowflake rose about 35% after hours on 33% sales growth plus a $6 billion AWS deal and Natoma acquisition, while Constellation Energy fell nearly 4% and Boston Scientific weakened after cautious guidance. Lululemon rose on a standstill agreement tied to board restructuring, and Dick’s Sporting Goods fell after boosting EPS guidance but trimming 2026 sales outlook.

Analysis

The tape is being driven less by macro breadth than by a narrow set of idiosyncratic catalysts that all reinforce the same factor exposure: AI monetization, governance resets, and “quality growth” rerating. That is constructive for semis and AI infrastructure near-term, but it also makes the market more fragile: when leadership is this concentrated, one disappointing guide from a bellwether can unwind multiple layers of passive and momentum demand in a single session.

Snowflake’s reaction matters more than the headline beat because the AWS deal and MCP acquisition suggest the market is starting to value data plumbing as an AI deployment bottleneck, not just a software subscription story. If that thesis holds, the second-order winners are adjacent data-management, orchestration, and inference-optimization vendors rather than the model builders themselves; over the next 6-12 months, that should keep spend rotating from experimentation to production tooling. The risk is that these deals inflate near-term sentiment faster than free-cash-flow conversion, creating a classic “multiple before margins” setup.

AppLovin is the cleaner momentum expression because its upside is tied to conversion-rate compounding rather than opaque TAM expansion. Still, a move like this can become self-defeating if execution expectations reset too high; the stock likely trades on quarterly proof points for the next 2-3 earnings cycles, not the long-dated 2030 target. On the other side, Boston Scientific looks like a guidance credibility problem, not a one-product issue—if management is signaling flat sequential growth in a previously important growth engine, med-tech multiple compression can spill into other procedure-dependent names.

The more interesting contrarian setup is in the consumer/governance names. Lululemon’s board reset may improve strategic flexibility, but it also tells you the real debate is about growth durability, not just control; that often precedes a period of multiple stabilization rather than immediate upside. Constellation’s pullback looks more like duration-risk re-rating than a fundamental change in power demand, which means it can rebound quickly if rates ease or if the market re-prices nuclear as an AI power bottleneck again.

Key Decisions for Investors

• Long SNOW vs short a basket of mature large-cap software (e.g., MSFT/ORCL-style proxies) for 1-3 months: capture the market’s willingness to pay for AI infrastructure enablers while hedging broad software multiple compression. Risk/reward is favorable if the AWS/Natoma narrative keeps converting into follow-through bookings.
• Buy APP on pullbacks into the next earnings window; use a 6-9 month horizon and size modestly because the stock is now a high-expectation compounder. Best risk/reward is a call spread rather than outright stock if implied volatility remains elevated.
• Short BSX or buy downside puts for 1-2 quarters: the market is likely underestimating how quickly a flat-growth procedural franchise gets de-rated when a named catalyst stalls. Pair against a higher-quality med-tech peer to isolate execution risk.
• Fade CEG weakness selectively only if rates stabilize: use a 3-6 month horizon and structure via call spreads rather than cash equity. The thesis is that the move is more factor-driven than fundamental, but don’t fight duration until the bond market confirms.
• Accumulate LULU only if the governance overhang compresses the multiple into a cleaner entry; otherwise wait 1-2 earnings cycles for the board reset to translate into product and channel decisions. Best setup is as a relative long versus weaker discretionary names, not as a standalone momentum chase.